ClinicalTrials.gg
Not yet recruitingNCT07649720PATENCYUpdated Nov 20, 2026

NaviCam Patency Capsule to Verify Gastrointestinal Patency

An interventional study of NaviCam Patency Capsule in Intestinal Stricture, Crohn Disease and NSAID (Non-Steroidal Anti-Inflammatory Drug) Induced Enteropathy, sponsored by AnX Robotica Corp.. Not yet recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by AnX Robotica Corp. · Not applicable, Interventional, and Screening

How we know

Updated Nov 20, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Planned enrollment
365th of 528
25 · median 60
Started
2027
with 3 others
No phase
128 of 660
28 open now
Primary completion
2027-09
later than 75 of 162 live
Registered
644th of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 365th largest by planned enrollment of the 528 interventional ones that give a count, is one of 4 that started in 2027, is one of 128 with no phase, reaches primary completion later than 75 of the 162 other live ones, and was the 644th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

Participants included in this study will first swallow a patency capsule and then undergo an abdominal X-ray scan within 30 hours after swallowing the capsule to confirm weather the capsule is still in the body.

Read the detailed description

If the X-ray scan indicates that the capsule is not in the body or shows that the patency capsule is in the colonic area or if an intact patency capsule is found in the bowel movement, it proves that the intestine is patent, and the patient can undergo an examination using capsule endoscopy. If the X-ray scan shows that the capsule is still in the small bowel area, it indicates that there may be stricture(s) in the intestines, and then small bowel capsule endoscopy may not be performed.

The patency capsule is a disposable medical device composed of medicinal excipients in the shape of a dissolvable passive capsule and will dissolve over time if not excreted.

03

Conditions studied

  • Intestinal Stricture
  • Crohn Disease
  • NSAID (Non-Steroidal Anti-Inflammatory Drug) Induced Enteropathy
  • Abdominal Pain
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with suspected or known intestinal stricture (with medical history records, physical examination records, and imaging evidence within the last 6 months.
  • Patients suffering from Crohn's Disease
  • Patients with long-term use of non-steroidal anti-inflammatory drugs.
  • Patients with abdominal symptoms related to intestinal stricture.
  • Patients with chronic inflammatory diseases.
  • Patients with difficulty with balloon-assisted endoscopy (BAE).
  • Patients with a history of small bowel obstruction.
  • Patients with a history of intestinal resection surgery.

Exclusion criteria

Exclusion Criteria:

  • Patients with esophageal obstruction or swallowing disorder diseases.
  • Patients who are ineligible for surgery or refuse to undergo any abdominal surgery.
  • Patients with known allergies or other or intolerance to the medications used in this study.
  • Patients with pacemakers or other implanted electronic devices such as cochlear implants, magnetic metal drug infusion pumps, neurostimulators.
  • Pregnant women
  • Patients currently enrolled in another drug or device clinical trial.
  • Other conditions deemed unsuitable for inclusion by the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Single arm patency capsule evaluation

    Participants will first swallow a patency capsule and then undergo an abdominal X-ray scan within 30 hours after swallowing the capsule to confirm whether the capsule is still in the body.

    Device: NaviCam Patency Capsule

Interventions

  • DeviceNaviCam Patency Capsule

    The NaviCam Patency Capsule is an accessory to the NaviCam capsule and is intended to verify adequate patency of the gastrointestinal tract prior to administration of the NaviCam capsule in patients with known or suspected strictures.

06

What researchers measure

Primary outcomes

  1. Safety of patency capsule

    The number of patients successfully passing the Patency Capsule within 30 hours compared to the number of patients where the Patency Capsule dissolves in patients with strictures.

    Time frame: 30 hours

  2. Efficacy of patency capsule

    The percentage of patients that successfully pass the Patency capsule within 30 hours.

    Time frame: 30 hours

07

Study locations

1 site
08

References and documents

Publications

  • Takeda K, Tashimo H, Miyakawa K, Shimada M, Ohshima N, Tamura A, Nagai H, Matsui H. Patency Capsule Aspiration. Intern Med. 2020 Apr 15;59(8):1071-1073. doi: 10.2169/internalmedicine.4012-19. Epub 2020 Jan 9. PubMed 31915319 ↗
  • Okoli A, Ammannagari N, Mazumder M, Nakkala K. When the dissolvable does not dissolve: an agile patency capsule mystery. Am J Gastroenterol. 2014 Apr;109(4):605-7. doi: 10.1038/ajg.2013.435. No abstract available. PubMed 24698874 ↗
  • Mitselos IV, Katsanos K, Tsianos EV, Eliakim R, Christodoulou D. Clinical Use of Patency Capsule: A Comprehensive Review of the Literature. Inflamm Bowel Dis. 2018 Oct 12;24(11):2339-2347. doi: 10.1093/ibd/izy152. PubMed 29718225 ↗
  • Spada C, Shah SK, Riccioni ME, Spera G, Marchese M, Iacopini F, Familiari P, Costamagna G. Video capsule endoscopy in patients with known or suspected small bowel stricture previously tested with the dissolving patency capsule. J Clin Gastroenterol. 2007 Jul;41(6):576-82. doi: 10.1097/01.mcg.0000225633.14663.64. PubMed 17577114 ↗
  • Herrerias JM, Leighton JA, Costamagna G, Infantolino A, Eliakim R, Fischer D, Rubin DT, Manten HD, Scapa E, Morgan DR, Bergwerk AJ, Koslowsky B, Adler SN. Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy. Gastrointest Endosc. 2008 May;67(6):902-9. doi: 10.1016/j.gie.2007.10.063. Epub 2008 Mar 19. PubMed 18355824 ↗
  • Kopylov U, Nemeth A, Cebrian A, Wurm Johansson G, Thorlacius H, Fernandez-Urien Sainz I, Koulaouzidis A, Eliakim R, Toth E. Symptomatic retention of the patency capsule: a multicenter real life case series. Endosc Int Open. 2016 Sep;4(9):E964-9. doi: 10.1055/s-0042-112588. Epub 2016 Aug 8. PubMed 27652302 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Sep 2027, 7 months later.

Of 302 interventional studies with no phase under Crohn Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 65. This study's planned 7 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Jun 2026 → Feb 2027, primary completion Dec 2026 → Sep 2027 and completion Mar 2027 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2026
First posted
Jun 16, 2026
StartEst.
Feb 15, 2027was Jun 2026
Primary completionEst.
Sep 30, 2027was Dec 2026
CompletionEst.
Oct 15, 2027was Mar 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 15, 2026→Feb 15, 2027
Nov 20, 2026
Primary completion
Dec 15, 2026→Sep 30, 2027
Nov 20, 2026
Study completion
Mar 15, 2027→Oct 15, 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Start date Jun 15, 2026→Feb 15, 2027
    Primary completion Dec 15, 2026→Sep 30, 2027
    Study completion Mar 15, 2027→Oct 15, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07649720
Lead sponsor
AnX Robotica Corp.
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Feb 15, 2027 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Tim Thomas, RAC
Contact
tim.thomas@anxrobotics.com
770-480-2911
Rockford G Yapp, MD
principal investigator · Digestive Health Services

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion